US 11,992,481 B2
Use of 2-substituted indazoles for the treatment and prophylaxis of autoimmune diseases
Alexandra Rausch, Berlin (DE); Stefan Joachim Jodl, Kleinmachnow (DE); Jörn Krätzschmar, Berlin (DE); Ulrich Bothe, Berlin (DE); and Nicole Schmidt, Wuppertal (DE)
Assigned to Bayer Pharma Aktiengesellschaft, Berlin (DE)
Filed by Bayer Pharma Aktiengesellschaft, Berlin (DE)
Filed on Feb. 16, 2022, as Appl. No. 17/673,644.
Application 17/673,644 is a continuation of application No. 16/863,330, filed on Apr. 30, 2020, abandoned.
Application 16/863,330 is a continuation of application No. 16/306,506, abandoned, previously published as PCT/EP2017/062535, filed on May 24, 2017.
Claims priority of application No. 16172507 (EP), filed on Jun. 1, 2016.
Prior Publication US 2022/0249456 A1, Aug. 11, 2022
Int. Cl. A61K 31/4439 (2006.01); A61P 19/02 (2006.01); A61P 29/00 (2006.01); A61P 37/06 (2006.01)
CPC A61K 31/4439 (2013.01) [A61P 19/02 (2018.01); A61P 29/00 (2018.01); A61P 37/06 (2018.01)] 12 Claims
OG exemplary drawing
 
1. A method of treating multiple sclerosis, in a subject in need thereof, comprising:
administering to the subject an effective amount of a compound, wherein the compound is:
N-[2-(3-Hydroxy-3-methylbutyl)-6-(2-hydroxypropan-2-yl)-2H-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide; or
N-{6-(2-Hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2H-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide,
or a pharmaceutically acceptable salt thereof.